Pharma Circle Panelist
Antoine Henninot
Director medicinal chemistry, Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Dr. Henninot is the Director of Chemistry at Takeda, San Diego, CA. He is leading discovery efforts in the peptide chemistry and bioconjugation group to generate novel peptide and oligonucleotide therapeutics that target gastrointestinal disease. Before joining Takeda, Dr. Henninot was the lead on multiple drug discovery projects and peptide chemistry efforts at the Ferring Research Institute, San Diego, CA. He obtained his M.Sc. at the Universite de Lille 1 in France and his Pharm.D. at the Universite de Lille 2. He stayed on to complete his Ph.D. in Medicinal Chemistry and Chemical Biology, under the supervision of Prof. Benoit Deprez and in collaboration with LFB Biotechnologie, working on identifying small molecule modulators of antibody post-translational modifications.